It is known that serum H D lipoproteins* can destabilize the lipid bilayer structure of liposomes by removal of phospholipid, so that the more destabilization, the more rapid the clearance of vesicles from the circulation of injected animals (Senior & Gregoriadis, 1982a,b; Gregoriadis, 1983). The aim of this work is to determine whether liposomal stability, as assessed by retention of entrapped markers, is improved in animals deficient in lipoproteins, and if so, whether this will lead to prolonged blood clearance. In addition we have investigated in oitro the effect of lipoproteins other than H D lipoproteins on liposomal stability, by using physiological concentrations of lipoproteins in the presence of lipoprotein-deficient plasma and at physiological temperature.
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Induction of plasma lipoprotein deficiency in mice is brought about by administration of 4-amino-pyrazolo-[3,4-djpyrimidine, an adenine anti-metabolite (Senior et al., 1983) . Doses of 60-70mg of drug/kg mouse wt. are given intraperitoneally on 3-4 consecutive days, leading to plasma cholesterol values of 0.2 f 0.1 mM/1 (cf 3.4+ 1.3 mM/1 for normal animals). Small unilamellar liposomes composed of egg phosphatidylcholine with tracer [3H]phosphatidylcholine were prepared by sonication at 4°C in presence of 0.2~-carboxyfluorescein. After centrifugation to remove larger vesicles, free dye was separated from entrapped dye by gel chromatography through Sepharose 6B (Senior et al., 1983). For studies in uiuo, 0.2ml of small unilamellar liposomes (0.87-1.0mg of phospholipid) were injected intravenously into 20-25g mice, and 2 5~1 blood samples were withdrawn at time intervals, diluted in 0.1 M-sodium phosphate buffer, pH 7.4, containing 1 % NaCl and 0.02% KCl (phosphate-buffered saline) and latent carboxyfluorescein and 3H radioactivity were measured as described by Senior et al. (1983) .
Liposomes injected intravenously into normal animals are cleared from the circulation rapidly, with less than 5% of the injected dose remaining in the blood after 30min (see Fig. 1 ). However, animals given three injections of the drug show a much slower rate of clearance of liposomes than do normal animals. Animals given four injections show an even slower clearance (1.24 h half-life) ( An example of plasma lipoprotein deficiency occurring in man is phosphatidylcholine :cholesterol acyltransferase deficiency characterized by low concentrations of plasma HD lipoproteins. A sample of plasma from a patient with phosphatidylcholine :cholesterol acyltransferase deficiency on incubation with phosphatidylcholine liposomes was less active in promoting solute release than was plasma from a normal control. Our results suggest that clinical application of drug-containing liposomes must take into account fluctuations in plasma HD lipoproteins, and perhaps other factors which could alter liposomal membrane permeability in vivo and thus influence drug fate and effect.
Liposomes have often been proposed for use as drug carriers (Mayhew & Papahadjopoulos, 1983) . The ability of liposomes to encapsulate drugs within their internal aqueous space or in the lipid bilayer makes them a versatile carrier system which may improve the efficacy of drugs in one of two ways. First, by acting as a slow release system, liposomes may modify the pharmacokinetics of drugs so as to prolong effective plasma drug levels. Second, being a microscopic carrier system, liposomes may transport and deliver drugs directly to cells.
The successful use of the second approach requires first that liposomes be directed specifically to the target cell, and second that they be capable of delivering the encapsulated drug to the cells once they reach them. Both of these characteristics can be examined by experiments in uitro, and we will here review our investigations which have been carried out to achieve these aims.
The targeting of liposomes to specific cell types is most readily achieved by attaching ligands to the liposome surface which will bind to determinants on the plasma membrane of the target cell. The most versatile ligands available are antibodies which can be produced to a wide * Present address : Department of Haematology, St. Bartholomews Hospital, West Smithfield, London ECI, U.K. variety of determinants on cells. In particular, monoclonal antibodies can be highly specific and preparations of monoclonals, unlike polyclonal antisera, contain very little antibody with no reactivity for the target antigen. We have developed several methods for the attachment of antibodies to liposomes. Our first procedure (Heath et a[., 1981) involved the use of periodate-oxidized glycosphingolipids in the liposome membrane, which can be conjugated to antibodies by reductive amination with sodium cyanoborohydride. Subsequently, more efficient procedures were developed which involved thiol conjugation methods. In the first (Martin et al., 1981) , phosphatidylethanolamine was modified by reaction with succinimidyl 3-(2-pyridyldithi0)propionate. The resultant modified lipid was incorporated into liposomes and reacted efficiently with rabbit Fab' to form a dithiol bridge which can be reduced by glutathione or other thiol-reducing agents. A more stable linkage was achieved by a similar procedure (Martin & Papahadjopoulos, 1982) in which phosphatidylethanolamine was reacted with succinimidyl 4-(p-maleimidopheny1)butyrate to give a modified phospholipid with an alkylating moiety. This lipid, after incorporation into liposomes, reacted rapidly with rabbit Fab' to form a thioether bond which cannot be reversed by reducing agents. We have also efficiently conjugated monoclonal antibodies to liposomes bearing the same maleimide derivative (Heath et al., 1983~) . Conjugation requires the introduction of thiol residues on to the antibody by reaction with succinimidyl 3-(2-pyridyldithio)propionate and mild reduction with dithiothreitol at pH4.5 (Carlsson et al., 1978) . The latter method is now most frequently used in this laboratory as it is both efficient and can be applied to any
